Department of Clinical Pathology, National Cancer Institute, Cairo University, Egypt.
Medical Oncology Department, National Cancer Institute, Cairo University, Egypt.
Asian Pac J Cancer Prev. 2023 Mar 1;24(3):1027-1036. doi: 10.31557/APJCP.2023.24.3.1027.
Colorectal cancer (CRC) is a major health problem Worldwide, Egypt shows a high rate of early CRC in the world as 35% of 1,600 Egyptian CRC patients were under 40 with threefold increased risk of death within 5 years. DNA methylation-based biomarkers as methylated Septin9 (mSEPT9) has a promising role for detecting CRC. As well as set of nuclear matrix proteins associated with changes in the nuclear structure/architecture. detection of these nuclear proteins resulted in identification of biomarkers that are specific for colon cancer. Particular interest has been placed on colon cancer specific antigen-2(CCSA-2).
A total of 30 newly diagnosed CRC patients, 7 colonic adenoma patients, and 15 age- and sex-matched control subjects were recruited in this study. Plasma mSEPT9was assayed by Epi procolon kit, CCSA-2 by ELISA and, Occult blood in stool by Guaiac-based fecal occult blood test. The level of Colon Cancer mSEPT9 and CCSA-2 were carried on CRC patients both preoperatively and three months postoperatively.
mSEPT9 has 96.7% sensitivity and 95.5% specificity in differentiating colorectal cancer patients from non-malignant cases. Also, our study showed a highly statistically significant difference between the pre and three months postoperative expression of mSEPT9 in colorectal cancer as there was a dramatically decrease in the expression of mSEPT9 postoperatively (p value < 0.001). The CCSA-2 at the cutoff level of >1.43 would provide 93.3% sensitivity and 90.9% specificity in differentiation between malignant and non-malignant cases. Also, the study showed that there is a statistically significant difference between colorectal cancer patients preoperatively and postoperatively according to CCSA-2 with dramatic decrease in its level postoperatively (p value > 0.001).
The plasma SEPT9 DNA methylation level and Serum CCSA-2 could be used as promising non-invasive methods for observing the CRC patients postsurgical response to predict the occurrence of complete remission or relapses.
结直肠癌(CRC)是一个全球性的主要健康问题,埃及在世界范围内表现出较高的早期 CRC 发生率,在 1600 例埃及 CRC 患者中,有 35%的患者年龄在 40 岁以下,其 5 年内死亡风险增加三倍。基于 DNA 甲基化的生物标志物,如甲基化 Septin9(mSEPT9),在检测 CRC 方面具有很大的应用潜力。还有一组与核结构/架构变化相关的核基质蛋白。这些核蛋白的检测导致了对特异性结肠癌的生物标志物的识别。特别关注的是结肠癌特异性抗原-2(CCSA-2)。
本研究共招募了 30 例新诊断的 CRC 患者、7 例结肠腺瘤患者和 15 例年龄和性别匹配的对照者。采用 Epi procolon 试剂盒检测血浆 mSEPT9,采用 ELISA 法检测 CCSA-2,采用基于愈创木脂的粪便隐血试验检测粪便潜血。在术前和术后 3 个月对 CRC 患者进行了结肠癌症 mSEPT9 和 CCSA-2 的水平检测。
mSEPT9 在区分结直肠癌患者和非恶性病例方面具有 96.7%的敏感性和 95.5%的特异性。此外,我们的研究表明,mSEPT9 在结直肠癌患者术前和术后 3 个月的表达之间存在高度统计学差异,术后 mSEPT9 的表达明显下降(p 值<0.001)。在 >1.43 的临界值下,CCSA-2 可以提供 93.3%的敏感性和 90.9%的特异性,以区分恶性和非恶性病例。此外,该研究表明,根据 CCSA-2,术前和术后的结直肠癌患者之间存在统计学差异,术后其水平明显下降(p 值>0.001)。
血浆 SEPT9 DNA 甲基化水平和血清 CCSA-2 可作为观察 CRC 患者术后对完全缓解或复发发生反应的有前途的非侵入性方法。